https://www.ardelyxmedical.com/poster-presentation/effect-of-tenapanor-on-treatment-satisfaction-degree-of-relief-and-quality-of-life-for-patients-with-irritable-bowel-syndrome-with-constipation-2022/ 2022-06-30T16:33:44+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-has-early-onset-of-action-in-treating-symptoms-of-irritable-bowel-syndrome-with-constipation-t3mpo-1-and-t3mpo-2-trials-2022/ 2022-06-30T16:34:11+00:00 https://www.ardelyxmedical.com/poster-presentation/long-term-treatment-with-tenapanor-improves-abdominal-pain-and-other-abdominal-symptoms-associated-with-ibs-c-2022/ 2022-06-30T16:34:37+00:00 https://www.ardelyxmedical.com/poster-presentation/efficacy-of-tenapanor-in-improving-ibs-c-abdominal-symptoms-a-post-hoc-analysis-of-multi-item-abdominal-score-from-the-26-week-phase-3-t3mpo-2-study-2022/ 2022-06-30T16:35:04+00:00 https://www.ardelyxmedical.com/poster-presentation/potential-of-tenapanor-as-a-treatment-for-chronic-idiopathic-constipation-a-post-hoc-analysis-from-the-phase-3-t3mpo-1-and-t3mpo-2-studies-for-irritable-bowel-syndrome-with-constipation-in-adults-20/ 2022-06-30T16:38:02+00:00 https://www.ardelyxmedical.com/poster-presentation/reduction-of-serum-phosphate-with-tenapanor-in-patients-with-chronic-kidney-disease-on-maintenance-dialysis-with-severe-hyperphosphatemia-2022/ 2022-06-30T16:49:55+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-plus-phosphate-binder-reduces-interdialytic-weight-gain-in-patients-with-chronic-kidney-disease-on-hemodialysis-post-hoc-analysis-of-the-amplify-study-2022/ 2022-06-30T16:50:21+00:00 https://www.ardelyxmedical.com/poster-presentation/assessment-of-diarrhea-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c-treated-with-tenapanor-a-pooled-safety-analysis-of-the-phase-3-studies-2023/ 2023-06-30T16:31:45+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-can-improve-abdominal-symptoms-independent-of-changes-in-bowel-movement-frequency-in-adult-patients-with-ibs-c-2023/ 2023-06-30T16:32:16+00:00 https://www.ardelyxmedical.com/poster-presentation/improvement-in-bloating-and-overall-complete-spontaneous-bowel-movement-response-with-tenapanor-treatment-a-post-hoc-analysis-of-the-ibs-c-clinical-studies-2023/ 2023-06-30T16:32:44+00:00 https://www.ardelyxmedical.com/poster-presentation/evaluation-of-tenapanor-efficacy-in-clinical-and-demographic-subgroups-of-patients-with-irritable-bowel-syndrome-with-constipation-2023/ 2023-06-30T16:33:09+00:00 https://www.ardelyxmedical.com/poster-presentation/trial-in-progress-r-ally-a-phase-3-randomized-double-blind-placebo-controlled-study-to-assess-safety-and-efficacy-of-tenapanor-in-pediatric-patients-with-ibs-c-2023/ 2023-06-30T16:35:32+00:00 https://www.ardelyxmedical.com/poster-presentation/assessment-of-diarrhea-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c-treated-with-tenapanor-a-pooled-safety-analysis-of-the-phase-3-studies-2023-2/ 2023-06-30T16:36:02+00:00 https://www.ardelyxmedical.com/poster-presentation/management-of-irritable-bowel-syndrome-with-constipation-ibs-c-a-nursing-perspective-2023/ 2023-06-30T16:36:26+00:00 https://www.ardelyxmedical.com/poster-presentation/preliminary-blinded-safety-data-from-r-ally-a-phase-3-randomized-double-blind-placebo-controlled-study-of-tenapanor-in-pediatric-patients-with-ibs-c-2023/ 2023-06-30T16:36:59+00:00 https://www.ardelyxmedical.com/poster-presentation/analysis-of-patient-reported-treatment-satisfaction-and-abdominal-score-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c-treated-with-tenapanor-2023/ 2023-06-30T16:37:33+00:00 https://www.ardelyxmedical.com/poster-presentation/safety-analysis-of-tenapanor-monotherapy-vs-sevelamer-carbonate-in-patients-on-maintenance-dialysis-with-hyperphosphatemia-2023/ 2023-06-30T16:46:59+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-in-combination-with-phosphate-binders-improves-short-and-long-term-control-of-serum-phosphate-sp-in-patients-on-dialysis-with-hyperphosphatemia-2023/ 2023-06-30T16:47:26+00:00 https://www.ardelyxmedical.com/poster-presentation/an-in-depth-analysis-of-serum-phosphate-changes-in-patients-with-ckd-on-dialysis-results-from-the-phreedom-study-2023/ 2023-06-30T16:47:52+00:00 https://www.ardelyxmedical.com/poster-presentation/post-hoc-analyses-of-serum-phosphate-changes-with-tenapanor-in-black-african-american-and-white-patients-on-maintenance-dialysis-2023/ 2023-06-30T16:48:15+00:00 https://www.ardelyxmedical.com/poster-presentation/patient-education-improves-adherence-to-tenapanor-treatment-in-optimize-study-2023/ 2023-06-30T16:48:43+00:00 https://www.ardelyxmedical.com/poster-presentation/optimal-initiation-of-tenapanor-treatment-analyzed-by-baseline-phosphate-binder-dose-a-sub-analysis-of-the-optimize-study-2023/ 2023-06-30T16:49:07+00:00 https://www.ardelyxmedical.com/poster-presentation/evaluation-of-changes-in-serum-fgf23-with-tenapanor-treatment-in-patients-with-chronic-kidney-disease-on-dialysis-2023/ 2023-06-30T16:49:31+00:00 https://www.ardelyxmedical.com/poster-presentation/efficacy-of-tenapanor-in-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c-a-post-hoc-analysis-of-patients-with-and-without-prior-use-of-other-ibs-c-prescription-medications-from-the-p/ 2024-06-30T16:28:18+00:00 https://www.ardelyxmedical.com/poster-presentation/comparing-the-efficacy-of-tenapanor-in-irritable-bowel-syndrome-with-constipation-in-hispanic-vs-non-hispanic-patients-a-post-hoc-analysis-of-patients-in-the-phase-3-t3mpo-1-and-t3mpo-2-studies-2024/ 2024-06-30T16:28:54+00:00 https://www.ardelyxmedical.com/poster-presentation/patients-with-irritable-bowel-syndrome-with-constipation-from-the-ibs-in-america-2024-real-world-survey-experience-burdensome-symptoms-beyond-constipation-2024/ 2024-06-30T16:30:13+00:00 https://www.ardelyxmedical.com/poster-presentation/irritable-bowel-syndrome-with-constipation-poses-a-substantial-burden-to-patient-overall-health-status-and-quality-of-life-results-from-the-ibs-in-america-2024-real-world-survey-2024/ 2024-06-30T16:30:43+00:00 https://www.ardelyxmedical.com/poster-presentation/educational-needs-related-to-irritable-bowel-syndrome-with-constipation-ibs-c-management-across-disciplines-a-comparison-of-nurse-practitioners-physician-assistants-and-physicians-2024/ 2024-06-30T16:31:12+00:00 https://www.ardelyxmedical.com/poster-presentation/patient-perception-of-phosphate-lowering-treatment-regimen-improves-adherence-to-therapy-2024/ 2024-06-30T16:43:57+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-treatment-added-to-phosphate-binders-improved-long-term-serum-phosphate-control-as-measured-by-reduction-in-average-daily-phosphate-area-under-the-curve-2024/ 2024-06-30T16:44:28+00:00 https://www.ardelyxmedical.com/poster-presentation/treatment-response-to-tenapanor-categorized-by-age-and-comorbidities-a-post-hoc-analysis-of-the-phreedom-study-2024/ 2024-06-30T16:44:58+00:00 https://www.ardelyxmedical.com/poster-presentation/addition-of-tenapanor-and-reduction-of-phosphate-binders-improved-phosphate-control-similarly-in-patients-undergoing-hemodialysis-and-peritoneal-dialysis-2024/ 2024-06-30T16:45:25+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-reduces-serum-phosphate-with-similar-efficacy-and-tolerability-profiles-when-added-to-various-phosphate-binders-2024/ 2024-06-30T16:45:52+00:00 https://www.ardelyxmedical.com/poster-presentation/sustained-phosphate-reduction-assessed-by-serum-phosphate-area-under-the-curve-with-tenapanor-is-associated-with-reduced-fibroblast-growth-factor-23-in-patients-with-chronic-kidney-disease-and-hyperph/ 2024-06-30T16:46:21+00:00 https://www.ardelyxmedical.com/poster-presentation/safety-and-tolerability-of-tenapanor-in-pediatric-patients-with-irritable-bowel-syndrome-with-constipation-an-analysis-of-blinded-safety-data-from-a-phase-3-study-and-its-open-label-extension-2025/ 2025-06-30T16:24:28+00:00 https://www.ardelyxmedical.com/poster-presentation/treatment-satisfaction-with-tenapanor-ibsrela-real-world-survey-of-patients-with-irritable-bowel-syndrome-with-constipation-2025/ 2025-06-30T16:25:08+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-improves-abdominal-bloating-symptoms-in-patients-with-ibs-c-experiencing-moderate-to-severe-bloating-2025/ 2025-06-30T16:25:35+00:00 https://www.ardelyxmedical.com/poster-presentation/reduction-in-gastrointestinal-visits-and-portal-messaging-following-tenapanor-ibsrela-initiation-in-patients-in-community-gastrointestinal-practices-2025/ 2025-06-30T16:26:09+00:00 https://www.ardelyxmedical.com/poster-presentation/neither-tenapanor-nor-its-major-metabolite-were-detected-in-the-breast-milk-of-healthy-lactating-females-after-4-days-of-dosing-a-phase-1-open-label-pharmacokinetic-study-2025/ 2025-06-30T16:26:52+00:00 https://www.ardelyxmedical.com/poster-presentation/patient-reported-ibs-c-symptom-severity-correlates-positively-with-financial-burden-ibs-in-america-2024-real-world-survey-2025/ 2025-06-30T16:27:23+00:00 https://www.ardelyxmedical.com/poster-presentation/ibs-in-america-2024-real-world-survey-patients-report-differences-in-ibs-management-support-and-health-related-quality-of-life-across-demographic-groups-2025/ 2025-06-30T16:27:51+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-treated-patients-using-over-the-counter-antidiarrheal-agents-had-decreased-stool-frequency-and-improved-stool-consistency-2025/ 2025-06-30T16:41:20+00:00 https://www.ardelyxmedical.com/poster-presentation/etelcalcetide-utilization-rates-decreased-and-parathyroidectomy-rates-increased-following-the-incorporation-of-calcimimetics-into-the-end-stage-kidney-disease-bundle-2025/ 2025-06-30T16:42:44+00:00 https://www.ardelyxmedical.com/poster-presentation/real-world-effectiveness-of-tenapanor-xphozah-for-treatment-of-hyperphosphatemia-in-united-states-patients-on-dialysis-2025/ 2025-06-30T16:43:04+00:00 https://www.ardelyxmedical.com/poster-presentation/treatment-satisfaction-with-tenapanor-xphozah-real-world-survey-of-patients-with-end-stage-renal-disease-and-hyperphosphatemia-2025/ 2025-06-30T16:43:31+00:00 https://www.ardelyxmedical.com/poster-presentation/tenapanor-improves-combined-symptoms-of-abdominal-bloating-pain-and-complete-spontaneous-bowel-movement-frequency-in-patients-with-ibs-c-experiencing-moderate-to-severe-bloating-aanp-2026/ 2026-06-30T16:23:41+00:00